Generating high-purity cardiac and endothelial derivatives from patterned mesoderm using human pluripotent stem cells
Nathan J Palpant1, Lil Pabon2,3,4, Clayton E Friedman1,3,4
1The Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia.
Nature Protocols
|December 2, 2016
Summary
This study presents a 2-week protocol for efficiently differentiating human pluripotent stem cells into cardiac and endothelial cells. This method establishes a common platform for generating cardiovascular progenitors for disease research and cell therapy.
Area of Science:
- Stem cell biology
- Developmental biology
- Cardiovascular research
Background:
- Human pluripotent stem cells (hPSCs) are crucial for studying human development and therapeutic cell generation.
- Efficient differentiation into specific cardiovascular lineages remains a challenge.
Purpose of the Study:
- To develop a protocol for efficient directed differentiation of hPSCs into cardiomyocytes and distinct endothelial cell (EC) subtypes.
- To establish a common platform for generating cardiovascular progenitors from hPSCs.
Main Methods:
- A 2-week monolayer-directed differentiation protocol using varying concentrations of activin A and bone morphogenetic protein 4 (BMP4).
- Induction of mesodermal subtypes mimicking cardiogenic and hemogenic mesoderm.
- Maturation of derived ECs to >90% CD31+/VE-cadherin+ definitive ECs.
Main Results:
- High-efficiency derivation of cardiomyocytes and distinct EC subtypes from hPSCs without cell sorting.
- Demonstrated functional assays for EC blood-forming potential and lumen formation.
- Achieved endothelial differentiation efficiencies surpassing previous protocols.
Conclusions:
- This protocol offers a novel, common platform for directed differentiation of cardiomyocytes and EC subtypes from hPSCs.
- The derived cardiovascular progenitors hold significant potential for disease modeling and therapeutic applications.
- This advancement is critical for understanding cardiovascular diseases and developing cell-based therapies.


